Keyfactor, the industry leader in digital trust for modern enterprises, has been named to the 2025 Fortune Best Workplaces in Technology™ List. This recognition marks another milestone in the ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that met all primary and co-primary endpoints.